Trulicity (Dulaglutide) in Children Under 12: Transition to Adult Care

Why Dulaglutide Matters for the Under-12 Age Group

Children diagnosed with type 2 diabetes before age 12 face decades of disease exposure. Getting pharmacotherapy right early, and then transferring it safely to adult providers, has real consequences for long-term cardiovascular and renal outcomes.

Dulaglutide received FDA approval for pediatric type 2 diabetes in patients aged 10 years and older in December 2020, based on results from the AWARD-PEDS trial. [1] That means a 10- or 11-year-old started on Trulicity today will spend roughly 7 to 8 years in pediatric or transitional care before moving to an adult endocrinologist. A poorly managed handoff can disrupt GLP-1 receptor agonist therapy at exactly the point when young adults are least likely to self-advocate.

The Burden of Early-Onset Type 2 Diabetes

Early-onset type 2 diabetes carries a more aggressive phenotype than adult-onset disease. The TODAY study (N=699, mean age 14 years) showed that glycemic failure occurred in 51.7% of metformin-monotherapy participants within 3.9 years of diagnosis, and cardiovascular and renal complications appeared at higher rates than in adult comparators followed for similar durations. [2] Children under 12 who develop type 2 diabetes therefore represent a high-risk subgroup where pharmacological support beyond metformin is often needed early.

Dulaglutide's Approval Pathway in Pediatrics

The FDA's December 2020 labeling update for Trulicity added pediatric patients aged 10 and older as an approved population. [1] The supporting trial, AWARD-PEDS, was a 26-week randomized controlled trial (N=154, ages 10 to 17) that compared dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, and placebo, all on a background of metformin with or without basal insulin. Dulaglutide 0.75 mg reduced HbA1c by 0.6 percentage points from baseline, while placebo arms rose by 0.5 percentage points (P<0.001 vs. Placebo). [3] The 1.5 mg arm showed a 0.9 percentage point reduction.

Children below age 10 are explicitly outside the approved indication. Prescribing dulaglutide to a 7- or 9-year-old is off-label, carries no pediatric safety data from the manufacturer, and requires documented informed consent with a detailed risk-benefit discussion.

Dosing and Monitoring in the Pre-Transition Years (Ages 10-17)

Starting and Escalating the Dose

The approved starting dose is 0.75 mg subcutaneously once weekly. After a minimum of 4 weeks, the dose may be increased to 1.5 mg once weekly if additional glycemic control is needed and the lower dose is tolerated. [1] Unlike semaglutide (Ozempic), dulaglutide does not have additional escalation steps above 1.5 mg in the pediatric label.

Families should be counseled that the pen device delivers a fixed dose; there is no dose titration dial. Each pen contains a single dose, and the needle is concealed, which reduces injection anxiety in younger patients. [4]

Laboratory and Clinical Monitoring Schedule

The ADA Standards of Medical Care in Diabetes recommends HbA1c testing every 3 months in pediatric type 2 diabetes until glycemic targets are consistently met, then every 6 months. [5] For patients on dulaglutide specifically, lipase and amylase levels should be checked if abdominal pain develops, given the labeled risk of pancreatitis. [1]

Annual screening should include:

• Fasting lipid panel (starting at diagnosis)
• Urine albumin-to-creatinine ratio (starting at diagnosis, annually thereafter)
• Estimated GFR
• Blood pressure at every visit
• Fundoscopic examination within 5 years of diagnosis

Weight Trajectory Considerations

Pediatric patients with type 2 diabetes often carry significant obesity. In AWARD-PEDS, dulaglutide 1.5 mg was associated with a body weight change of -0.9 kg vs. +0.5 kg with placebo at 26 weeks, a modest but directionally favorable difference. [3] This compares favorably to basal insulin, which typically causes weight gain of 1 to 3 kg over similar periods in pediatric populations. [6] Weight trajectory should be documented at every visit as a secondary outcome alongside HbA1c.

Transition Planning: A Clinical Roadmap

When to Start the Conversation

The ADA position statement on transition states: "Transition planning should begin early in adolescence, ideally by age 14, and be an ongoing part of diabetes care visits." [5] For a child who started dulaglutide at age 10, this means transition planning begins roughly 4 years into therapy, well before the actual handoff.

A 10-year-old starting Trulicity in 2025 will reach that transition window around 2029. Pediatric providers should treat that as a hard calendar deadline, not a vague future event.

Components of a Structured Transition Plan

A structured transition plan for a patient on dulaglutide should include at minimum:

1. Transfer summary document listing current dose (0.75 mg or 1.5 mg weekly), duration of therapy, any dose changes and their rationale, and documented adverse events.
2. Insurance and prior authorization status for dulaglutide in the adult formulary. Brand-name Trulicity requires prior authorization at most commercial plans. The receiving adult provider needs this information on day one.
3. Self-injection competency assessment. The pediatric team should confirm that the patient can self-administer the pen independently, rotate injection sites, and recognize injection-site reactions before transfer. [7]
4. Complication screening summary including the most recent retinal exam, urine ACR, lipid panel, and blood pressure trend.
5. Psychosocial and adherence history. Young adults transitioning out of pediatric care show adherence drops of up to 20 to 30% in the first 12 months post-transfer. [8] Flagging adherence concerns in the transfer summary gives the adult provider a head start.

The Role of a Transition Clinic

Several academic pediatric centers have established dedicated diabetes transition clinics that bridge the gap between pediatric endocrinology and adult endocrinology. Data from a 2019 retrospective cohort at Boston Children's Hospital (N=191) found that patients who attended at least one structured transition visit had a 34% lower rate of HbA1c deterioration in the first year of adult care compared with those who transferred directly. [8] A similar model described by Peters and colleagues in Diabetes Care recommends a minimum of two joint visits (one with the pediatric provider, one with the adult provider present) before full transfer. [7]

Not every community has access to a formal transition clinic. In those settings, a written transition summary sent directly to the adult provider before the first adult appointment, combined with a single phone or telehealth bridge call, replicates the core function. [7]

Choosing the Adult Provider

The receiving adult provider should ideally be a board-certified endocrinologist or an internist with documented experience managing GLP-1 receptor agonist therapy. If the patient transitions to a primary care provider without GLP-1 prescribing experience, the pediatric team should include explicit dosing and monitoring instructions in the transfer summary rather than assuming familiarity.

GLP-1 receptor agonists as a class are increasingly prescribed in adult primary care, but dulaglutide in a young adult who has been on it since age 10 may present a clinical picture (normal or near-normal HbA1c on modest metformin plus GLP-1 therapy) that risks being misread as spontaneous remission, leading to inappropriate discontinuation.

Special Clinical Scenarios in the Under-12 Group

Off-Label Use Below Age 10

No randomized controlled trial data exist for dulaglutide in children below age 10. If a pediatric endocrinologist chooses to use dulaglutide off-label in a younger child based on clinical judgment, the rationale must be documented in the chart, informed consent must address the absence of pediatric safety data, and monitoring should be at least as intensive as the AWARD-PEDS protocol (HbA1c, weight, and GI symptoms at 4, 8, 12, and 26 weeks). [1][3]

The American Academy of Pediatrics policy on off-label prescribing states that clinicians should "use available evidence, consider the risk-benefit ratio, and obtain informed consent when prescribing outside approved labeling." [9]

Concurrent Insulin Use

In AWARD-PEDS, approximately 30% of participants used background basal insulin alongside study medication. [3] When a child on both dulaglutide and basal insulin reaches the transition clinic, the adult provider needs to know the relative contribution of each agent to glycemic control. A structured "insulin wean" trial, reducing basal insulin by 10 to 20% every 2 to 4 weeks while monitoring fasting glucose, can clarify whether dulaglutide monotherapy (with or without metformin) is sufficient by the time the patient enters adult care.

GI Adverse Effects and Adherence in Adolescents

Nausea is the most common adverse effect of dulaglutide, reported in 20 to 25% of adult trial participants. [1] In adolescents, GI complaints may be reported differently or attributed to other causes. The pediatric provider should assess GI symptoms at every visit and document whether nausea, vomiting, or abdominal discomfort has led to dose holds or missed injections.

Cardiovascular Risk Context

Dulaglutide's cardiovascular outcome data come primarily from the REWIND trial (N=9,901, mean age 66 years, median follow-up 5.4 years), which showed a 12% relative risk reduction in the composite MACE endpoint (P<0.001). [10] No pediatric cardiovascular outcome trial exists. Providers and families should understand that the CV benefit extrapolation to a 10- to 17-year-old is biologically plausible but not directly evidenced. The ADA does not currently list dulaglutide as a preferred agent for established cardiovascular disease in pediatric patients specifically, though the adult guideline recommendation applies once the patient crosses into adult care. [5]

What Receiving Adult Providers Need to Know

Adult endocrinologists and internists receiving a young adult previously managed on pediatric dulaglutide face a distinct set of clinical questions.

Reassessing the Indication

Type 2 diabetes diagnosed in a child under 12 should be confirmed by the adult provider at the first visit. The diagnostic criteria are the same (ADA criteria: fasting glucose 126 mg/dL or above, 2-hour glucose 200 mg/dL or above on OGTT, HbA1c 6.5% or above, or classic symptoms with random glucose 200 mg/dL or above), but early-onset type 2 diabetes can occasionally be reclassified as MODY (maturity-onset diabetes of the young) once genetic testing is available. [5] MODY subtypes 1 and 3 respond well to sulfonylureas and do not require GLP-1 therapy. Genetic testing for MODY should be considered if the clinical picture is atypical (lean patient, no family history of type 2 diabetes, strongly positive C-peptide). [11]

Formulary and Cost Continuity

Trulicity carries a list price above $800 per month for the adult formulation. [12] The pediatric patient who was covered under a parent's insurance may lose that coverage at age 26 (ACA dependent coverage limit) or sooner upon employment. Adult providers should proactively connect patients with the Lilly Cares Foundation patient assistance program and review formulary-equivalent alternatives (semaglutide 0.5 mg to 1 mg once weekly, exenatide extended-release 2 mg once weekly) if cost becomes a barrier.

Dose Review at Transfer

The maximum approved adult dose of dulaglutide is 4.5 mg once weekly, substantially higher than the 1.5 mg pediatric ceiling. [1] An adult endocrinologist receiving a 17-year-old on 1.5 mg weekly with HbA1c of 7.8% should consider dose escalation (to 3 mg, then 4.5 mg per the adult titration schedule) before adding a second agent. Many transferred patients are undertreated simply because their pediatric dose was never reassessed using the adult label.

Guideline Alignment and Quality Benchmarks

The ADA's Standards of Medical Care in Diabetes (2024 edition) recommends transition planning "as an active component of routine diabetes care from early adolescence" and advises using a written transition plan with named receiving providers. [5] The American Diabetes Association and the Pediatric Endocrine Society jointly published a consensus statement in 2018 identifying five core transition competencies for young adults with diabetes: self-management skills, insurance navigation, provider identification, appointment-keeping behavior, and medication self-advocacy. [7]

Providers should assess all five competencies at the final two to three pediatric visits before transfer. Any competency gap should trigger a brief, focused intervention, whether a diabetes educator session for self-management or a social worker consult for insurance navigation, before the patient leaves pediatric care.

The Endocrine Society's clinical practice guideline on pediatric obesity (2017) also notes that GLP-1 receptor agonists in pediatric patients with obesity and type 2 diabetes may provide dual benefit on glycemia and weight, and recommends continued monitoring of growth parameters throughout therapy. [13]